# 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients

> **NCT02917720** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **European LeukemiaNet** · enrollment: 75 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **OTHER:** TKI discontinuation
- **DRUG:** nilotinib

## Key facts

- **NCT ID:** NCT02917720
- **Lead sponsor:** European LeukemiaNet
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-09
- **Primary completion:** 2026-09
- **Final completion:** 2027-09
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02917720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02917720, "2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02917720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*